An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments

Each year millions of nonhuman animals suffer in biomedical experiments for human health benefits. Clinical ethics demand that nonhuman animals are used in the development of pharmaceuticals and vaccines. Nonhuman animals are also used for fundamental biomedical research. Biomedical research that us...

Full description

Bibliographic Details
Main Author: Kay Peggs
Format: Article
Language:English
Published: MDPI AG 2015-07-01
Series:Animals
Subjects:
Online Access:http://www.mdpi.com/2076-2615/5/3/0376
id doaj-2d026faeb11545668ea5d1d4b41ca2d8
record_format Article
spelling doaj-2d026faeb11545668ea5d1d4b41ca2d82020-11-24T22:34:25ZengMDPI AGAnimals2076-26152015-07-015362464210.3390/ani5030376ani5030376An Insufferable Business: Ethics, Nonhuman Animals and Biomedical ExperimentsKay Peggs0Oxford Centre for Animal Ethics, School of Social, Historical and Literary Studies, University of Portsmouth, Milldam, Burnaby Road, Portsmouth PO1 3AS, Hampshire, UKEach year millions of nonhuman animals suffer in biomedical experiments for human health benefits. Clinical ethics demand that nonhuman animals are used in the development of pharmaceuticals and vaccines. Nonhuman animals are also used for fundamental biomedical research. Biomedical research that uses nonhuman animals is big business but the financial gains are generally occluded. This paper explores how such research generates profits and gains for those associated with the industry. Research establishments, scientists, laboratories, companies that sell nonhuman animal subjects, that supply equipment for the research, and corporations that market the resulting products are among those that benefit financially. Given the complex articulation of ethical codes, enormous corporate profits that are secured and personal returns that are made, the accepted moral legitimacy of such experiments is compromised. In order to address this, within the confines of the moral orthodoxy, more could to be done to ensure transparency and to extricate the vested financial interests from the human health benefits. But such a determination would not address the fundamental issues that should be at the heart of human actions in respect of the nonhuman animals who are used in experiments. The paper concludes with such an address by calling for an end to the denigration of nonhuman animals as experimental subjects who can be used as commodities for profit-maximisation and as tools in experiments for human health benefits, and the implementation of a more inclusive ethic that is informed by universal concern about the suffering of and compassion for all oppressed beings.http://www.mdpi.com/2076-2615/5/3/0376anthropocentricbiomedicalbusinessethicsexperimentsnonhuman animalsprofits
collection DOAJ
language English
format Article
sources DOAJ
author Kay Peggs
spellingShingle Kay Peggs
An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments
Animals
anthropocentric
biomedical
business
ethics
experiments
nonhuman animals
profits
author_facet Kay Peggs
author_sort Kay Peggs
title An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments
title_short An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments
title_full An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments
title_fullStr An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments
title_full_unstemmed An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments
title_sort insufferable business: ethics, nonhuman animals and biomedical experiments
publisher MDPI AG
series Animals
issn 2076-2615
publishDate 2015-07-01
description Each year millions of nonhuman animals suffer in biomedical experiments for human health benefits. Clinical ethics demand that nonhuman animals are used in the development of pharmaceuticals and vaccines. Nonhuman animals are also used for fundamental biomedical research. Biomedical research that uses nonhuman animals is big business but the financial gains are generally occluded. This paper explores how such research generates profits and gains for those associated with the industry. Research establishments, scientists, laboratories, companies that sell nonhuman animal subjects, that supply equipment for the research, and corporations that market the resulting products are among those that benefit financially. Given the complex articulation of ethical codes, enormous corporate profits that are secured and personal returns that are made, the accepted moral legitimacy of such experiments is compromised. In order to address this, within the confines of the moral orthodoxy, more could to be done to ensure transparency and to extricate the vested financial interests from the human health benefits. But such a determination would not address the fundamental issues that should be at the heart of human actions in respect of the nonhuman animals who are used in experiments. The paper concludes with such an address by calling for an end to the denigration of nonhuman animals as experimental subjects who can be used as commodities for profit-maximisation and as tools in experiments for human health benefits, and the implementation of a more inclusive ethic that is informed by universal concern about the suffering of and compassion for all oppressed beings.
topic anthropocentric
biomedical
business
ethics
experiments
nonhuman animals
profits
url http://www.mdpi.com/2076-2615/5/3/0376
work_keys_str_mv AT kaypeggs aninsufferablebusinessethicsnonhumananimalsandbiomedicalexperiments
AT kaypeggs insufferablebusinessethicsnonhumananimalsandbiomedicalexperiments
_version_ 1725727644730785792